Literature DB >> 26763434

Early Tumor-Infiltrating Dendritic Cells Change their Characteristics Drastically in Association with Murine Melanoma Progression.

Takeshi Nakahara1, Junna Oba2, Chie Shimomura2, Makiko Kido-Nakahara2, Masutaka Furue3.   

Abstract

Dendritic cells (DCs) have a critical effect on the outcome of adaptive immune responses against growing tumors. Tumor-infiltrating dendritic cells (TIDCs) play diverse roles in the regulation of tumor regression or growth, but the characteristics that distinguish those effects are obscure. In this study, we investigated the frequency, phenotype, and function of TIDCs over time from early stages of melanoma growth in mice. Flow cytometric analysis revealed that the tumors were infiltrated by a significant population of CD11c(+) major histocompatibility complex II(+) DCs, especially at an early stage of tumor growth. The allogeneic stimulatory capacity of TIDCs increased with tumor growth, whereas this capacity of DCs in lymph nodes decreased. TIDCs harvested at an early stage of melanoma (early TIDCs) accelerated tumor growth, but those harvested at a late stage (late TIDCs) delayed tumor progression when they were coinjected with melanoma cells. Furthermore, coinjection of early TIDCs failed to induce full immunocompetent maturation of CD8(+) T cells, with much lower expression of IFN-γ, granzyme B, and perforin within the tumor microenvironment. In conclusion, TIDCs change their characteristics from an immunoinhibitory to an immunostimulatory phenotype over time in association with tumor progression.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26763434     DOI: 10.1038/JID.2015.359

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma.

Authors:  Lien De Beck; Robin Maximilian Awad; Veronica Basso; Noelia Casares; Kirsten De Ridder; Yannick De Vlaeminck; Alessandra Gnata; Cleo Goyvaerts; Quentin Lecocq; Edurne San José-Enériz; Stefaan Verhulst; Ken Maes; Karin Vanderkerken; Xabier Agirre; Felipe Prosper; Juan José Lasarte; Anna Mondino; Karine Breckpot
Journal:  Front Immunol       Date:  2022-05-12       Impact factor: 8.786

Review 2.  Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma.

Authors:  Kristian M Hargadon
Journal:  Front Immunol       Date:  2017-11-20       Impact factor: 7.561

Review 3.  Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment.

Authors:  Heidi Harjunpää; Marc Llort Asens; Carla Guenther; Susanna C Fagerholm
Journal:  Front Immunol       Date:  2019-05-22       Impact factor: 7.561

4.  Cryo-thermal therapy induces macrophage polarization for durable anti-tumor immunity.

Authors:  Kun He; Shengguo Jia; Yue Lou; Ping Liu; Lisa X Xu
Journal:  Cell Death Dis       Date:  2019-03-04       Impact factor: 8.469

5.  Role of ERK Pathway in the Pathogenesis of Atopic Dermatitis and Its Potential as a Therapeutic Target.

Authors:  Nahoko Zeze; Makiko Kido-Nakahara; Gaku Tsuji; Eriko Maehara; Yuki Sato; Sawako Sakai; Kei Fujishima; Akiko Hashimoto-Hachiya; Masutaka Furue; Takeshi Nakahara
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

Review 6.  Control of Dendritic Cell Function Within the Tumour Microenvironment.

Authors:  Yukti Hari Gupta; Abida Khanom; Sophie E Acton
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

7.  TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM.

Authors:  Alice L Hung; Russell Maxwell; Debebe Theodros; Zineb Belcaid; Dimitrios Mathios; Andrew S Luksik; Eileen Kim; Adela Wu; Yuanxuan Xia; Tomas Garzon-Muvdi; Christopher Jackson; Xiaobu Ye; Betty Tyler; Mark Selby; Alan Korman; Bryan Barnhart; Su-Myeong Park; Je-In Youn; Tamrin Chowdhury; Chul-Kee Park; Henry Brem; Drew M Pardoll; Michael Lim
Journal:  Oncoimmunology       Date:  2018-05-24       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.